Informations générales (source: ClinicalTrials.gov)
Assessment of Executive and Socio-cognitive Functions in Child and Adult Survivors of Primary Brain Tumor: Impact on Patients' and Relatives' Quality of Life. (NEUROCOG-QOL)
Interventional
N/A
University Hospital, Angers (Voir sur ClinicalTrials)
février 2016
septembre 2018
29 juin 2024
Significant advances in primary malignant brain tumors (PBT) treatment have led to
dramatically improved survival, both in children and adults. However, survival has not
come without a cost and aggressive treatment methods associated with significant
long-term adverse effects, often referred to as "late effects" (Panigrahy & Blüml, 2009).
These effects are the medical, physical, cognitive and psychosocial sequelae associated
with cancer and its treatments that generally emerge two to five years after treatment
ends (e.g., Landier & Bhatia, 2008).
The most serious challenge survivors of brain tumors face may be cognitive dysfunction.
One especially important cognitive domain is executive functioning, which refers to
essential factors such as problem-solving, goal-directed behavior and the ability to
maintain stable interpersonal relationships (Lezak et al., 2004). Despite the potential
impact of executive impairments on behavioral regulation and quality of life, few studies
were conducted with survivors of PBT specifically for the assessment of executive
functioning. Another fundamental neuro-cognitive domain is social cognition, which refers
to the ability to understand the intentions and beliefs of others (Frith & Singer, 2008).
Social cognitive deficits are expected to impair autonomy and relationships, but scarce
attention has been devoted to the study of social cognition in survivors of PBT and no
study has attempted to compare socio-cognitive data and measures of health-related
quality of life. It is noteworthy that executive function and socio-cognitive skills
improve throughout childhood and adolescence, and improvements in these skills have
frequently been attributed to maturation of the brain, especially the prefrontal cortex
(e.g., Tamnes et al., 2010). This suggests a greater impact of the disease and its
treatment on these functions in children/adolescents.
Etablissements
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CHU Angers - Angers - France | Didier Le Gall | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
- Age between 8 and 59
- Children/adolescents and adults who have been treated by chemotherapy and/or
radiotherapy and/or neurosurgery, subsequent to the diagnosis of a primary brain
tumor
- The end of treatment must be comprised between 2 and 5 years at the time of the
assessment, as argued above.
- Age between 8 and 59
- Children/adolescents and adults who have been treated by chemotherapy and/or
radiotherapy and/or neurosurgery, subsequent to the diagnosis of a primary brain
tumor
- The end of treatment must be comprised between 2 and 5 years at the time of the
assessment, as argued above.
- Sensory disturbances (e.g., visual, auditory) incompatible with the achievement of
the tasks
- Language or praxis deficits inconsistent with the achievement of the tasks
- Neurological disease other than PBT
- secondary brain tumor
- Psychiatric history (consultation with a psychiatrist of the University Hospital if
doubt)
- Insufficient French language proficiency